rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Iovance Biotherapeutics, Inc.

IOVA · Nasdaq

Health CareBiotechnologyLeading

IOVA stood above a rising 150-day average in 42 of the last 52 weekly readings, including each of the last 42 weeks. It is 125.5% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
42 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
273 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 42 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$483K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders273+7 on the quarter
New · exited44 · 37
Reported value$1.2B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202636,957,681$153.7M+5,877,176+18.9%
MHR FUND MANAGEMENT LLCunchanged · filed 14 Aug 202628,967,103$120.5M00.0%
STATE STREET CORPadded · filed 7 Aug 202624,478,268$101.8M+7,030,160+40.3%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 202619,010,697$79.1M+5,323,264+38.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202618,204,248$75.7M+1,586,511+9.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 202614,388,999$59.9M+2,688,155+23.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202610,324,826$43.0M+1,752,228+20.4%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20268,525,919$35.5M-888,373−9.4%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20266,460,449$26.9M+3,814,747+144.2%
Palo Alto Investors LPreduced · filed 17 Aug 20265,296,209$22.0M-1,053,354−16.6%
31 Mar 2023 – 30 Jun 2026
187229270Mar 23Dec 23Dec 24Sep 25Jun 26

News

Everyone who traded it

Noah Berkowitz Company insiderChief Medical Officer · last 30 Sep 20260 · 0
Frederick G. Vogt Company insiderInterim CEO & General Counsel · last 8 Sep 20263 · 0
Igor Bilinsky Company insiderChief Operating Officer · last 8 Sep 20260 · 0
Raj K. Puri Company insiderChief Regulatory Officer · last 8 Sep 20261 · 0
Daniel Gordon Kirby Company insiderChief Commercial Officer · last 10 Aug 20261 · 0
Corleen M. Roche Company insiderChief Financial Officer · last 6 Aug 20260 · 0
Athena Countouriotis Company insiderDirector · last 16 Jun 20260 · 0
Iain D. Dukes Company insiderDirector · last 16 Jun 20263 · 0
Michael Weiser Company insiderDirector · last 16 Jun 20261 · 0
Ryan D. Maynard Company insiderDirector · last 16 Jun 20261 · 1
Finckenstein Friedrich Graf Company insiderChief Medical Officer · last 5 Jun 20260 · 0
Wendy L. Yarno Company insiderDirector · last 13 Jun 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202534.3%
Operating profit marginFY 2025 · to 31 Dec 2025-153%
Free cash flow marginFY 2025 · to 31 Dec 2025-128%
Return on capital employedFY 2025 · to 31 Dec 2025-52.1%
Research spendFY 2025 · to 31 Dec 2025114%
Cash and equivalentsFY 2025 · to 31 Dec 2025$163.1M
Free cash flowFY 2025 · to 31 Dec 2025−$336.2M

Analyst forecasts

No analyst forecasts yet.